Concomitant Radiotherapy and New Drugs in Metastatic Breast Cancer

Launched by FONDAZIONE POLICLINICO UNIVERSITARIO CAMPUS BIO-MEDICO · Jun 11, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating how well patients with advanced breast cancer tolerate radiation treatment when they are also receiving new types of drugs, such as targeted therapies and immunotherapy. The main goal is to see how these treatments work together and whether they can be safely given at the same time. The trial is currently looking for participants, and it is open to all genders between the ages of 65 and 74 who have stage IV breast cancer and are already on ongoing systemic treatment, like targeted therapies or immunotherapy.

To be eligible for this trial, patients should not have received radiation treatment on the same area before, and they must be candidates for radiation, whether it's to relieve symptoms (palliative) or to try to cure the cancer (curative). If you join this study, you can expect to be closely monitored during your treatment to assess how well you are tolerating both the radiation and the new medications. This trial aims to provide important information that could help improve treatment options for people with metastatic breast cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients suffering from stage IV breast cancer
• • Ongoing systemic treatment including: molecular targeted therapy, conjugated antibodies, monoclonal antibodies, tyrosine kinase inhibitors, immunotherapy (immunocheckpoint inhibitors)
• • Candidates for radiation treatment (both palliative and curative).
• Exclusion Criteria:
• • Previous radiation treatment on the same site
• • Absolute contraindications to radiotherapy
• • Systemic treatment administered as part of a clinical trial